Axamozide

This classification denotes an antipsychotic agent with the molecular formula C21H22ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MCG9O55T6K, chemically known as ( -)-1-(1-(1,4-benzodioxan-2-ylmethyl)-4-piperidyl)-5-chloro-2-benzimidazolinone but generally known as axamozide, which bears US NIH Compound Identifier 170359. European Medicines Agency schedules Axamozide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05621MIG. The term AXAMOZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, No. 5, 1985, List 25). AXAMOZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule axamozide under HS 29349990 and SITC 51579. As of Q4 2014, AXAMOZIDE remains the US FDA Preferred Term for this commodity. Axamozide bears US NLM identifiers UMLS ID C2346888 and NCI Concept Code C73281. SMILES: CLC1CC2[NH]C(=O)N(C3CCN(CC3)CC3OC4C(OC3)CCCC4)C2CC1.